AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01303081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chosen Deposits
Description: Participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine/anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
Study NCT01303081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive Deposits (Pari-Mutuel)
Description: Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
Study NCT01303081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
Study NCT01622010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Allied Health Education Class Option
Description: An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
Study NCT01622010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Allied Health Education Class Option
Description: An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
Study NCT01622010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy treatment intervention on referral
Description: The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
Study NCT01622010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment intervention on referral
Description: The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
Study NCT01622010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keeping the Beat with Physiotherapy: Heart Failure edition
Description: Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
Study NCT01226901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.
Study NCT01875939 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral WCK2349
Description: The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
Study NCT01875939 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IV WCK771
Description: The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
Study NCT00524914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apomorphine
Description: Acute apomorphine subcutaneous 3 mg
Study NCT00524914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo subcutaneous
Study NCT00584935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, IV, or SC
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT
Study NCT04121156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS treatment
Description: 2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions
Study NCT04121156 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham (placebo) HD-tDCS
Description: Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 5 consecutive twice daily sessions
Study NCT04270071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxin Shengmai
Description: Yangxin Shengmai Granules
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given PO or IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Give PO
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Give PO
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT, IV, or PO
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, or PO
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02112916 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02112916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01054261 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: avanafil
Description: 200 mg avanafil tablet QD
Study NCT04200911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune
Description: Sirolimus 1mg capsules
Study NCT00286793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101
Description: Oral
Study NCT04885933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sarcopenia measurement
Description: BIA for fat free muscle mass hand grasp strength
Study NCT00681304 — intervention group
Intervention type: OTHER
Intervention: ultrasound scan
Description: The only study procedure involved in this project is for subjects to undergo an ultrasound scan during their radiation therapy simulation. The ultrasound is done at this time, so it can be co-registered to the routine breast treatment planning CT scan.
Study NCT03839732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Score of abdominal aorta calcifications
Description: Radiographs showing VC will be used to assess whether the computer assisted VC scoring (primary objective) and Quantitative Vertebral Morphometry (QVM, limited to lumbar spine, secondary objective n.1) through the Calcify2D software are less variable with respect to the traditional visual scoring of VC and QVM.
Study NCT04270071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yangxin Shengmai placebo
Description: Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.
Study NCT04270071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitroglycerin tablets
Description: Be used when angina attack
Study NCT01651403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: * Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg.
Study NCT01651403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TDF Placebo
Description: * Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily.
Study NCT03566303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 15 mg
Description: Rivaroxaban 15 mg BID
Study NCT03566303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Warfarin
Description: Warfarin
Study NCT02719379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)
Study NCT02719379 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)
Study NCT02719379 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)
Study NCT01818674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic Behavioral Health Full Program (education curriculum in classroom setting, plus full social interaction program)
Description: A 6-month intervention program (sessions and educational materials) aims to increase knowledge and skills in diabetes self-management and peer support and monitoring. The curriculum include causes of diabetes, prevention of complications, symptoms, self-management strategies, diet, exercise, peer monitoring and support by trained Project nurses from MoH health centers, local physicians, and university professors. Each class will provide 2-3 hours of discussion to foster active class participation and engagement.
Study NCT01818674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic Behavioral Health Basic Program (education-only in classroom setting; no structured social interactions)
Description: This basic program (6 month) aims to increase participants knowledge about diabetes self-management, but without structured social interaction programming. While group classroom setting is still used for delivery of the educational curriculum, the education program in group B have no group-based or team-building activities, group goal setting, and classroom program is lecture style with more limited class participation and interaction.
Study NCT03595930 — intervention group
Intervention type: DRUG
Intervention: Arnuity
Description: ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
Study NCT04227743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryobiopsy
Description: . The cryobiopsy samples will be obtained by advancement of the cryoprobe into the working channel of the bronchoscope to touch the tip of the endobronchial tumor. The freezing time will be approximately 4 seconds. Then, flexible bronchoscope together with tissue sample attached to the tip of the frozen probe will be extracted outside the bronchial tree. The tissue sample will be released from the probe's tip by plunging it into saline at room temperature. FB will be reintroduced after cryobiopsy to evaluate and control the bleeding.
Study NCT02432469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APP intervention
Description: The APP contains education materials about secondary intervention of coronary artery disease, patients can surf and read them very easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback from patients at 8 pm every day. The APP also pushes a patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-management on blood pressure, blood lipid, blood glucose, physical activity, diet and body weight. APP pushes series of recommendations right after patients' finishing the questionnaire to help them improve their secondary prevention.
Study NCT00661739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
Study NCT02417584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positive airway pressure (PAP)
Description: Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
Study NCT03444233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 7 days fruit-rich diet, 7 days HFCS-rich diet
Study NCT02236065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood therapy
Study NCT02236065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study NCT01422525 — intervention group
Intervention type: PROCEDURE
Intervention: spectral domain optical coherence tomography
Description: RNFL thickness measurement using spectral domain optical coherence tomography at baseline, 1, 3 and 6 months postoperatively.
Study NCT05100043 — intervention group
Intervention type: BIOLOGICAL
Intervention: IL-4 and IFN-γ measurements
Description: Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants
Study NCT04251884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic (ropivacaine)
Description: Patients randomized in the treatment arm will receive a sonography-guided pudendal nerve block
Study NCT04251884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic (ropivacaine)
Description: Patients randomized in the treatment arm will receive a sonography-guided pudendal nerve block
Study NCT04059692 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cervical manipulation intervention
Description: Cervical manipulative technique
Study NCT04059692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo intervention
Description: Sham intervention
Study NCT04270071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroglycerin tablets
Description: Be used when angina attack
Study NCT04436562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Poziotinib
Description: Single oral administration of 8 mg (as the hydrocholoride salt) of \[14C\]-poziotinib
Study NCT02025140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer controlled anesthesia
Description: The IANB by the computer controlled local anesthetic device CCLAD and periodontal ligament anesthesia by the CCLAD
Study NCT02025140 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional anesthesia syringe
Description: Active control
Study NCT04444193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PD-L1 Monoclonal Antibody
Study NCT04444193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Oral Product
Description: Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
Study NCT01797861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Half-dose photodynamic therapy (PDT)
Description: At exactly 15 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will take place. The area that has to be treated with the PDT laser is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (approximately 3 minutes) fluorescein angiogram. The spot size will be defined based on diameter of the hyperfluorescent area on ICG angiography plus 1mm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
Study NCT01797861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micropulse laser (ML) treatment
Description: The following ML treatment settings will be used: a power of 1800 mW\*, a duty cycle of 5%, frequency of 500 Hz, exposure time of 0.2 s per spot, spot size: 125 µm, minimal distance of spot from fovea: 500 µm.~\* Subthreshold treatment is desired, meaning that no visible reaction due to laser treatment has to be seen in the retina. In virtually all patients, a power of 1800 mW wil not produce a visible discoloration of the retina after application of a laser spot with the aforementioned settings. If retinal discoloration is seen at a power of 1800 mW the power will be reduced with steps of 300 mW until there is no visible reaction. The first laser test spot will always be applied just outside the macular area.
Study NCT02365389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTZ vaginal gel
Description: MTZ vaginal gel once daily for 5 days
Study NCT02365389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional MTZ vaginal gel
Description: Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
Study NCT03927521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal HIFU using PET-MRI/68Ga-PSMA imaging guidance
Description: Focal HIFU treatment will be conducted with the Focal One® device using the PET-MRI/68Ga-PSMA imaging. The treatment area will be defined using PET-MRI/68Ga-PSMA imaging data and 3D biopsies.